Tadalafil
Product Images NDC 70518-3697

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-3697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure of tadalafil, showing its molecular framework with fused rings, including an indole-like structure and a lactam ring system.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

This image displays four line graphs comparing blood pressure differences between tadalafil and placebo over time. The graphs show changes in standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, with measurements taken at multiple time points up to 96 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

Two line graphs showing changes in standing and supine systolic blood pressure over 24 hours post-dose. The top graph compares tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg in standing systolic blood pressure. The bottom graph shows the same comparison for supine systolic blood pressure over time.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin at 08:00 and 20:00. The x-axis represents time after administration, and the y-axis represents systolic blood pressure changes. Different line styles correspond to each treatment and dosing time.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic graph depicting plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The plot shows concentration decreasing over time with error bars for variability.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph showing the change from baseline in IPSS total score over a 12-week duration of treatment, comparing tadalafil 5 mg versus placebo. The y-axis represents the change in score, and the x-axis shows weeks of treatment (0, 4, 8, 12). The tadalafil group shows a greater decrease in IPSS score compared to placebo, with statistical significance indicated.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration between tadalafil 5 mg and placebo groups. The graph shows measurements at 0, 1, 4, 8, and 12 weeks, with tadalafil group data represented by solid circles and placebo by open triangles, indicating a greater reduction in score for tadalafil over time.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph depicting least-squares mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride compared to Placebo/Finasteride. The y-axis shows change values from 0 to -7, while the x-axis marks weeks 0, 4, 12, and 26. Data points indicate greater improvement with Tadalafil/Finasteride over time versus placebo, with statistical significance annotations.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph comparing change from baseline in IPSS total score over treatment duration in weeks between Tadalafil 5 mg and placebo groups. The graph shows Tadalafil 5 mg with solid circles decreasing steadily, while placebo with open triangles decreases less sharply. A significance marker (p<0.01) is indicated on the graph.*

FDA Label Image

Remedy_label (Remedy Label)

Label for tadalafil 5 mg tablets, repackaged by RemedyRepack Inc. The package contains 250 tablets. It includes a barcode, QR code, and cautions such as tablets should not be split and should be kept out of reach of children. The manufacturer is noted as Unichem Labs Ltd., Goa, India.*

FDA Label Image

Mm2 (Tadalafil 5mg 70518 3697 01)

Label for tadalafil 5 mg tablet by RemedyRepack Inc. The label states RX only and includes NDC 70518-3697-01. It shows quantity as 1 tablet and cautions that tablets should not be split. Manufactured by Unichem Labs Ltd. in Goa, India. Storage instructions and repackager contact information are also provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.